BRISTOL-MYERS SQUIBB NAMES STEPHEN BEAR TO HEAD WORLDWIDE OTC DRUG BUSINESS
BRISTOL-MYERS SQUIBB NAMES STEPHEN BEAR TO HEAD WORLDWIDE OTC DRUG BUSINESS as part of a management reorganization of the company's international consumer products businesses. Formerly executive VP of Bristol-Myers Squibb's U.S. Consumer Products Group, Bear has been named president of Worldwide Consumer Medicines with responsibility for "the global activities" of the Bristol-Myers Products Division and the company's consumer businesses in Japan, the company said. Bear, 42, will report directly to Bristol-Myers Squibb President and CEO Charles Heimbold.
More from Archive
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
A new pilot aims to take Brazil closer to ‘digital transformation.’
More from Pink Sheet
Ensitrelvir, Shionogi's treatment for COVID-19, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
AbbVie didn’t get everything it sought from a citizen petition but may still have the upper hand over smaller rivals after FDA gives makers of animal-derived thyroid medications a year to seek approval. If the agency removes compounded products, it could face more pricing pushback.
The findings are consistent with some other research and likely are due to obesity patients becoming more connected to needed health care services.